Investigating how RBFOX2 affects pancreatic cancer progression through splicing changes
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
['FUNDING_R01'] · H. LEE MOFFITT CANCER CTR & RES INST · NIH-11079453
This study is looking at a protein called RBFOX2 to see how it affects pancreatic cancer and how changes in the way genes are spliced might make the cancer grow and spread more aggressively, which could help find new ways to treat the disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | H. LEE MOFFITT CANCER CTR & RES INST (nih funded) |
| Locations | 1 site (TAMPA, UNITED STATES) |
| Trial ID | NIH-11079453 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the RBFOX2 protein in pancreatic cancer, particularly how its deregulation influences cancer progression through alternative splicing of RNA. By using advanced genetic screening techniques, the study aims to identify specific splicing events that contribute to the aggressiveness of pancreatic ductal adenocarcinoma (PDAC). The researchers will explore how changes in splicing patterns can affect cancer cell behavior, including their ability to invade and differentiate. This work could lead to new insights into the mechanisms of pancreatic cancer and potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those with aggressive or poorly differentiated forms of the disease.
Not a fit: Patients with other types of cancer or those without a diagnosis of pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating pancreatic cancer by targeting the splicing mechanisms involved in its progression.
How similar studies have performed: While the specific role of RBFOX2 in pancreatic cancer is being explored in this research, similar studies have shown that targeting splicing mechanisms can be effective in other cancer types, indicating potential for success.
Where this research is happening
TAMPA, UNITED STATES
- H. LEE MOFFITT CANCER CTR & RES INST — TAMPA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MANN, KAREN M — H. LEE MOFFITT CANCER CTR & RES INST
- Study coordinator: MANN, KAREN M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: cancer cell differentiation, Cancer Center